24 Exercise capacity improvement in adult congenital heart disease patients switching from bosentan to macitentan therapy
Abstract
Purpose
Therapeutic options for patients with congenital heart disease (PAH-CHD) are limited. Endothelin receptor antagonists do play a role,1 however the recent MAESTRO trial showed that Macitentan only improved six-minute walk distance (6 MWD) in the control group.2 We report real world use of patients who switch from Bosentan to Macitentan in a single centre PAH-CHD cohort.Methods
Clinical data was...Paper Details
Title
24 Exercise capacity improvement in adult congenital heart disease patients switching from bosentan to macitentan therapy
Published Date
Feb 1, 2018
Journal
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History